# The impact of micronutrients and docosahexaenoic acid (DHA) on cognitive development of school-aged children: the NEMO studies

Submission date	Recruitment status  No longer recruiting	<ul><li>Prospectively registered</li></ul>		
19/12/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
19/12/2005	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
03/11/2008	Nervous System Diseases			

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Jan Willem van Klinken

#### Contact details

Unilever Food and Health Research Institute (UFHRI) P.O. Box 114 Vlaardingen Netherlands 3130 AC Jan-Willem-van.Klinken@Unilever.com

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

#### Scientific Title

The impact of micronutrients with or without docosahexaenoic acid (DHA) on cognitive development of school-aged children in Indonesia and South Australia: a randomised controlled trial

#### **Acronym**

**NEMO** 

#### Study objectives

An intervention with a fortified drink containing iron, zinc, vitamin A, vitamin C, folate, vitamin B-12 and B-6 and/or omega-3 polyunsaturated fatty acids over one year can improve cognitive performance in Australian well-nourished children and Indonesian marginally-nourished children.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Received from the local medical ethics committee

#### Study design

Multicentre, randomised, double blind, placebo controlled, factorial trial

## Primary study design

Interventional

# Secondary study design

Randomised controlled trial

#### Study setting(s)

Other

# Study type(s)

Treatment

#### Participant information sheet

## Health condition(s) or problem(s) studied

Cognitive development

#### Interventions

Children receiving fortified drink containing either:

- 1. Micronutrient mix (iron, vitamin A, vitamin C, vitamin B12, vitamin B6 at one recommended daily allowance [RDA], zinc at half RDA)
- 2.88 mg DHA and 22 mg EPA
- 3. Both
- 4. Placebo

#### Intervention Type

Supplement

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

Iron, zinc, vitamin A, vitamin C, folate, vitamin B-12 and B-6 and/or omega-3 polyunsaturated fatty acids

#### Primary outcome measure

Cognitive performance (working memory, attention and concentration, perceptual speed, problem solving, executive function, learning and memory, school performance)

#### Secondary outcome measures

- 1. Biochemical indicators (blood iron status, zinc status, folate, vitamin B12)
- 2. Fatty acids status (plasma EPA, DPA, DHA, ALA and total n-3 plasma mass)
- 3. Growth (weight, height, body mass index)

#### Overall study start date

01/08/2003

#### Completion date

01/04/2005

# **Eligibility**

#### Key inclusion criteria

- 1. Children aged 6-9 years of age from six selected schools in urban Jakarta and 42 public schools in Southern Australia
- 2. Parents or carers provided informed consent

#### Participant type(s)

**Patient** 

#### Age group

Child

#### Lower age limit

6 Years

#### Upper age limit

9 Years

#### Sex

Both

# Target number of participants

780

#### Key exclusion criteria

In the two study sites:

- 1. Children with severe physical and neurological health problems
- 2. No (intended) use of micronutrient/mineral and/or fatty acid supplements

In addition in Indonesia:

3. Children who are severely malnourished (weight/height Z-score less than or equal to -3 standard deviation [SD]) or severely anaemic (haemoglobin less than 8 g/l)

#### Date of first enrolment

01/08/2003

#### Date of final enrolment

01/04/2005

# Locations

#### Countries of recruitment

Australia

Indonesia

Netherlands

# Study participating centre Unilever Food and Health Research Institute (UFHRI)

Vlaardingen Netherlands 3130 AC

# Sponsor information

#### Organisation

Unilever Nederlands BV (The Netherlands)

#### Sponsor details

P.O. Box 160 Rotterdam Netherlands 3000 AD

#### Sponsor type

Industry

Website

http://www.unilever.nl/

#### **ROR**

https://ror.org/02436cs38

# Funder(s)

## Funder type

Not defined

#### Funder Name

Not provided at time of registration

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/10/2007		Yes	No